Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Review, H2 2016', provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted pipeline therapeutics. The report provides comprehensive information on the Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - The report reviews Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics and enlists all their major and minor projects - The report assesses Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) Overview 7 Therapeutics Development 8 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Stage of Development 8 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Therapy Area 9 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Indication 10 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Companies 14 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Products under Development by Universities/Institutes 16 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Companies Involved in Therapeutics Development 24 AnaBios Corporation 24 Astellas Pharma Inc. 25 AstraZeneca Plc 26 Flex Pharma, Inc. 27 Glenmark Pharmaceuticals Ltd. 28 Hydra Biosciences, Inc. 29 Johnson & Johnson 30 Pila Pharma AB 31 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Drug Profiles 32 ASP-7663 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 AZ-465 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 FLX-787 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 GRC-17536 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 HX-100 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 hydralazine hydrochloride - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 JNJ-41477670 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Small Molecules to Block TRPA1 and TRPV1 for Pain - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 Small Molecules to Block TRPA1 and TRPV1 for Pain and Inflammation - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Dormant Projects 50 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Discontinued Products 51 Transient Receptor Potential Cation Channel Subfamily A Member 1 (Ankyrin Like With Transmembrane Domains Protein 1 or Transformation Sensitive Protein p120 or TRPA1) - Featured News & Press Releases 52 Jun 15, 2016: Flex Pharma Initiates Phase 2 Efficacy Study in Multiple Sclerosis 52 May 25, 2016: Flex Pharma Initiates Human Efficacy Study with Single Molecule Tablet in Nocturnal Leg Cramps 52 Apr 19, 2016: Flex Pharma's Positive Human NLC Study Selected for Presentation at AAN Annual Meeting 53 Mar 14, 2016: Flex Pharma Positive Human NLC Study Selected for Late-Breaking Presentation at AAN Annual Meeting 54 Feb 02, 2016: Flex Pharma Announces Positive Human Efficacy in Nocturnal Leg Cramp Study 55 Jan 06, 2016: Hydra Biosciences to Present at the 8th Annual Biotech Showcase Conference in San Francisco on Jan. 11 56 Jan 06, 2016: Enrollment Completed in Flex Pharma's Exploratory Human Nocturnal Leg Cramp Study 56 Nov 10, 2015: Flex Pharma Announces FLX-787 as Clinical Drug Candidate 57 Oct 20, 2015: Flex Pharma Demonstrates Single Agent Efficacy and Dose Response in Reducing Human Muscle Cramps 58 Jul 28, 2015: Flex Pharma Announces Two Poster Presentations at Upcoming Scientific Meetings 58 Jul 07, 2015: Flex Pharma Announces Reduction of Muscle Cramping in Athletes 59 May 04, 2015: NSF Approves Flex Pharma's Proprietary Formulation under NSF's Certified for Sport Program 60 Apr 27, 2015: Flex Pharma Initiates Human Proof-of-Concept Efficacy Study in Nocturnal Leg Cramps 60 Apr 14, 2015: Hydra Biosciences Receives Approval from Health Canada to Begin Phase 1 Trial for HX-100 61 Feb 18, 2015: AAN Selects Flex Pharma Data for Oral Platform Presentation 61 Appendix 63 Methodology 63 Coverage 63 Secondary Research 63 Primary Research 63 Expert Panel Validation 63 Contact Us 63 Disclaimer 64
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Assessment by Monotherapy/Combination Products, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 20 Number of Products by Stage and Route of Administration, H2 2016 22 Number of Products by Stage and Molecule Type, H2 2016 23 Pipeline by AnaBios Corporation, H2 2016 24 Pipeline by Astellas Pharma Inc., H2 2016 25 Pipeline by AstraZeneca Plc, H2 2016 26 Pipeline by Flex Pharma, Inc., H2 2016 27 Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 28 Pipeline by Hydra Biosciences, Inc., H2 2016 29 Pipeline by Johnson & Johnson, H2 2016 30 Pipeline by Pila Pharma AB, H2 2016 31 Dormant Projects, H2 2016 50 Discontinued Products, H2 2016 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
